Here's Why You Should Add PODD Stock to Your Portfolio Now

1 day ago · Insulet Corporation’s PODD rapid commercial expansion and increasing market access capabilities for its Omnipod platform are poised to help it grow in the upcoming …

CouponFollow Extension

7%
OFF

Here's Why You Should Add PODD Stock To Your Portfolio Now

3 weeks from now

2 days ago · You can see the complete list of today’s Zacks #1 Rank stocks here. Omnicell, carrying a Zacks Rank #2 (Buy) at present, has an earnings yield of 3.7% compared with the …

zacks.com

9%
OFF

Here's Why You Should Buy Insulet (PODD) Stock Right Now

3 weeks from now

Mar 18, 2024 · In the past year, this Zacks Rank #2 (Buy) stock has decreased 47.9% against the 6.6% rise of the industry and 29.3% growth of the S&P 500 composite.

yahoo.com

46%
OFF

Here's Why You Should Retain Insulet (PODD) Stock For Now

3 weeks from now

Feb 16, 2024 · You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Stryker, carrying a Zacks Rank #2 at present, has an earnings yield of 3.46% against the …

nasdaq.com

9%
OFF

Here's Why You Should Retain Insulet (PODD) Stock For Now

3 weeks from now

Jun 21, 2023 · Here's Why You Should Retain Insulet (PODD) Stock for Now. Zacks Equity Research ... stock has increased 38.9% compared with the 19.8% fall of the industry and a …

yahoo.com

9%
OFF

Here's Why You Should Retain Insulet (PODD) Stock For Now

3 weeks from now

May 23, 2023 · You can see the complete list of today’s Zacks #1 Rank stocks here. Zimmer Biomet shares have increased 11.9% compared to the industry’s 29.6% decline in the past year.

nasdaq.com

8%
OFF

Here's Why You Should Invest In Insulet (PODD) Stock For Now

3 weeks from now

Here's Why You Should Invest in Insulet (PODD) Stock for Now. Zacks Equity Research ... stock has gained 38.8% compared with a 9% rise of the industry and a 10.8% rise of the S&P 500 …

yahoo.com

8%
OFF

Should You Continue To Retain PODD Stock In Your Portfolio Now?

3 weeks from now

Sep 4, 2024 · You can see the complete list of today’s Zacks #1 Rank stocks here. TransMedix Group’s earnings are expected to surge 255.8% in 2024. Its shares have soared 130.6% …

zacks.com

6%
OFF

Should You Continue To Retain PODD Stock In Your Portfolio Now?

3 weeks from now

Sep 4, 2024 · In the past year, this Zacks Rank #3 (Hold) stock has rallied 7.6% compared with the 15.5% growth of the industry and the 24.9% rise of the S&P 500 composite.

yahoo.com

8%
OFF

Here's Why You Should Hold On To Insulet (PODD) Stock For Now

3 weeks from now

Dec 13, 2021 · Over the past year, the Zacks Rank #3 (Hold) stock has gained 9.8% versus 2.2% fall of the industry and a 29.8% rise of the S&P 500. The renowned developer, manufacturer …

yahoo.com

10%
OFF

Here's Why You Should Add Cencora Stock To Your Portfolio Now

3 weeks from now

1 day ago · For fiscal 2025, adjusted EPS is estimated to be in the range of $14.80-$15.10, indicating growth of 8-10% from the prior-year level. The top line is projected to rise 7-9%.

nasdaq.com

7%
OFF

Here's Why You Should Add Nevro Stock To Your Portfolio Now

3 weeks from now

Jan 23, 2025 · This Zacks Rank #2 (Buy) company’s shares have lost 49.7% in the past six months against the industry’s 3.5% growth. The S&P 500 has increased 12.1% in the said …

yahoo.com

FAQs about Here's Why You Should Add PODD Stock to Your Portfolio Now Coupon?

Should you buy Podd Insulet Corporation (PDD)?

PODD Insulet Corporation’s PODD rapid commercial expansion and increasing market access capabilities for its Omnipod platform are poised to help it grow in the upcoming quarters. The rising adoption of Omnipod 5 also presents a promising growth opportunity. Besides, a sound financial position bodes well for the stock. ...

Should you buy Omnipod 5 (Podd) stock?

Omnipod 5 remains a disruptive force in the diabetes technology market as the only FDA-approved, fully disposable, pod-based AID system. Investors remain confident in the Insulet (PODD) stock due to the huge success of Omnipod 5. ...

How does Podd continue to grow?

Moreover, PODD continues to invest prudently in commercial expansion and market access capabilities by gradually expanding the salesforce, creating new territories and entering targeted pediatric centers. Omnipod 5, a New Area of Focus: Insulet’s game-changing Omnipod 5 stands out as the only FDA-cleared, fully disposable pod-based AID system. ...

Is Insulet Corporation (Podd) a good stock to buy?

Insulet Corporation PODD is well-poised to gain in the coming quarters, backed by the strength of its revolutionary Omnipod 5 Automated Insulin Delivery (“AID”) system. The continued market expansion of Omnipod DASH is also highly encouraging. Strong solvency is an added upside. ...

What is Podd's market capitalization?

The developer, manufacturer and distributor of insulin delivery systems has a market capitalization of $14.22 billion. PODD’s earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 67.5%. ...

Is Omnipod 5 a good investment?

Omnipod 5, a New Focus: Insulet has been making progress with respect to its development roadmap of the Omnipod Horizon (now Omnipod 5) automated insulin delivery (AID) system. Investors are optimistic about Insulet (PODD), led by the strong adoption of Omnipod 5 and its strong solvency position. ...